

D Adam Lauver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8498741/publications.pdf>

Version: 2024-02-01

21
papers

538
citations

932766

10
h-index

887659

17
g-index

21
all docs

21
docs citations

21
times ranked

937
citing authors

#	ARTICLE	IF	CITATIONS
1	Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 28-33.	3.3	159
2	Disodium Disuccinate Astaxanthin (Cardax) Attenuates Complement Activation and Reduces Myocardial Injury following Ischemia/Reperfusion. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 686-692.	1.3	65
3	Sulodexide: A Renewed Interest in This Glycosaminoglycan. Cardiovascular Drug Reviews, 2006, 24, 214-226.	4.4	65
4	Sildenafil Citrate for Prophylaxis of Nephropathy in an Animal Model of Contrast-Induced Acute Kidney Injury. PLoS ONE, 2014, 9, e113598.	1.1	53
5	Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting Hemostasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 794-800.	1.3	42
6	Contemporary use of and outcomes associated with ultra-low contrast volume in patients undergoing percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2019, 93, 222-230.	0.7	38
7	Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1114-1120.	1.3	28
8	Disodium Disuccinate Astaxanthin Prevents Carotid Artery Rethrombosis and ex vivo Platelet Activation. Pharmacology, 2008, 82, 67-73.	0.9	26
9	Formation, Reactivity, and Antiplatelet Activity of Mixed Disulfide Conjugates of Clopidogrel. Molecular Pharmacology, 2013, 83, 848-856.	1.0	14
10	Oral Pretreatment With Liposomal Glutathione Attenuates Reperfusion Injury in Rabbit Isolated Hearts. Journal of Cardiovascular Pharmacology, 2013, 61, 233-239.	0.8	12
11	Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 11-17.	1.3	10
12	Improving corrected QT; Why individual correction is not enough. Journal of Pharmacological and Toxicological Methods, 2022, 113, 107126.	0.3	8
13	CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel. Thrombosis and Haemostasis, 2014, 112, 1304-1311.	1.8	6
14	DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y ₁₂ antagonists. Pharmacology Research and Perspectives, 2019, 7, e00509.	1.1	4
15	Pleiotropic effects of clopidogrel. Purinergic Signalling, 2022, 18, 253-265.	1.1	4
16	Relationship of clinical adverse event reports to models of arrhythmia risk. Journal of Pharmacological and Toxicological Methods, 2019, 100, 106622.	0.3	2
17	Clopidogrel treatment inhibits P2Y ₂ -Mediated constriction in the rabbit middle cerebral artery. European Journal of Pharmacology, 2021, 911, 174545.	1.7	2
18	Endothelial P2Y ₂ -mediated vasoconstriction is inhibited in middle cerebral arteries of rabbits treated with clopidogrel. FASEB Journal, 2021, 35, .	0.2	0

#	ARTICLE	IF	CITATIONS
19	Which QT Correction Method is Most Consistent?. FASEB Journal, 2021, 35, .	0.2	0
20	RO3244794, an IP receptor antagonist, shortens the time to occlusion in a canine model of coronary artery thrombosis. FASEB Journal, 2008, 22, 640-640.	0.2	0
21	>Clopidogrel Rescues the Adverse Cerebral Vascular Effects Associated with Angiotensin II-Induced Hypertension. FASEB Journal, 2022, 36, .	0.2	0